MX2013001247A - 6- (1-metil-1h-pirazol-4-il) -3- )2-metil-2h-indazol-5-iltio)- [1, 2, 4] triazolo [4, 3-b] piridazina como inhibidor de c-met. - Google Patents
6- (1-metil-1h-pirazol-4-il) -3- )2-metil-2h-indazol-5-iltio)- [1, 2, 4] triazolo [4, 3-b] piridazina como inhibidor de c-met.Info
- Publication number
- MX2013001247A MX2013001247A MX2013001247A MX2013001247A MX2013001247A MX 2013001247 A MX2013001247 A MX 2013001247A MX 2013001247 A MX2013001247 A MX 2013001247A MX 2013001247 A MX2013001247 A MX 2013001247A MX 2013001247 A MX2013001247 A MX 2013001247A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- salt
- cancer
- met
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36933510P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/044926 WO2012015677A1 (en) | 2010-07-30 | 2011-07-22 | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013001247A true MX2013001247A (es) | 2013-03-18 |
Family
ID=44513148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001247A MX2013001247A (es) | 2010-07-30 | 2011-07-22 | 6- (1-metil-1h-pirazol-4-il) -3- )2-metil-2h-indazol-5-iltio)- [1, 2, 4] triazolo [4, 3-b] piridazina como inhibidor de c-met. |
Country Status (15)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2870178B1 (en) * | 2012-05-09 | 2017-07-12 | Eli Lilly and Company | Anti-c-met antibodies |
| CN103122000B (zh) | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环三唑类化合物 |
| KR101083177B1 (ko) | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| DK2084162T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
| PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
-
2011
- 2011-07-20 AR ARP110102632A patent/AR085183A1/es unknown
- 2011-07-22 WO PCT/US2011/044926 patent/WO2012015677A1/en active Application Filing
- 2011-07-22 EA EA201270818A patent/EA201270818A1/ru unknown
- 2011-07-22 MX MX2013001247A patent/MX2013001247A/es not_active Application Discontinuation
- 2011-07-22 BR BR112013002211A patent/BR112013002211A2/pt not_active IP Right Cessation
- 2011-07-22 US US13/188,496 patent/US8268836B2/en not_active Expired - Fee Related
- 2011-07-22 KR KR1020137002382A patent/KR20130052740A/ko not_active Application Discontinuation
- 2011-07-22 TW TW100126076A patent/TWI431008B/zh not_active IP Right Cessation
- 2011-07-22 JP JP2013521838A patent/JP5738412B2/ja not_active Expired - Fee Related
- 2011-07-22 AU AU2011282973A patent/AU2011282973B2/en not_active Expired - Fee Related
- 2011-07-22 EP EP11741372.4A patent/EP2598144B1/en not_active Not-in-force
- 2011-07-22 CN CN2011800371928A patent/CN103002898A/zh active Pending
- 2011-07-22 CA CA2805494A patent/CA2805494A1/en not_active Abandoned
- 2011-07-22 ES ES11741372.4T patent/ES2516940T3/es active Active
-
2012
- 2012-12-31 IN IN2924MUN2012 patent/IN2012MN02924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2598144A1 (en) | 2013-06-05 |
| JP2013532687A (ja) | 2013-08-19 |
| KR20130052740A (ko) | 2013-05-23 |
| TW201219393A (en) | 2012-05-16 |
| ES2516940T3 (es) | 2014-10-31 |
| CA2805494A1 (en) | 2012-02-02 |
| US20120028984A1 (en) | 2012-02-02 |
| WO2012015677A9 (en) | 2012-12-13 |
| AR085183A1 (es) | 2013-09-18 |
| US8268836B2 (en) | 2012-09-18 |
| AU2011282973A1 (en) | 2013-01-10 |
| BR112013002211A2 (pt) | 2016-05-24 |
| EP2598144B1 (en) | 2014-08-13 |
| AU2011282973B2 (en) | 2014-03-20 |
| JP5738412B2 (ja) | 2015-06-24 |
| TWI431008B (zh) | 2014-03-21 |
| EA201270818A1 (ru) | 2013-05-30 |
| IN2012MN02924A (US20070167479A1-20070719-C00034.png) | 2015-06-12 |
| WO2012015677A1 (en) | 2012-02-02 |
| CN103002898A (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10227329B2 (en) | Compounds useful for treating disorders related to RET | |
| AU2011282973B2 (en) | 6-(1-methyl-1H-pyrazol-4-yl)-3-(2-methyl-2H-indazol -5-ylthio)-[1,2,4] triazolo [4,3-b]pyridazine as a c-Met inhibitor | |
| EP2850082B1 (en) | 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer | |
| RU2326882C2 (ru) | Пиримидиновые соединения, обладающие антипролиферативной активностью (ii) | |
| CN109906227A (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
| CN109689641B (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
| EP3283642B1 (en) | Prognostic biomarkers for ttk inhibitor chemotherapy | |
| Wang et al. | Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors | |
| CA2952230C (en) | Pyrimidine compounds and methods using the same | |
| Wei et al. | Design, synthesis and biological evaluation of 7-((7H-pyrrolo [2, 3-d] pyrimidin-4-yl) oxy)-2, 3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer | |
| EP3661936B1 (en) | [1,2,4]triazolo[4,3-a]pyrazin-6(5h)-one derivatives | |
| KR20200011990A (ko) | 단백질 키나제 저해제로서 유용한 피리도퀴나졸린 유도체 | |
| CN116731030A (zh) | 几种呋喃并嘧啶-布洛芬杂合衍生物的合成方法及抗肿瘤的应用 | |
| CN115246832A (zh) | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |